Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 50

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 50
---
, there will be further dilution to new investors. In addition, to the extent we need to raise additional capital in the
future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock
offered in this offering.

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section
entitled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our
use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. We expect to use
the net proceeds of this offering, together with our existing cash and cash equivalents and marketable securities to fund the development of our product candidates and preclinical and drug discovery programs and for working capital and general
corporate purposes. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short- and intermediate term, investment-grade, interest-bearing
securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which
could cause our stock price to decline.

The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.

Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver
instructions to TD Cowen to sell shares of our common stock at any time throughout the term of the Sales Agreement. The number of shares that are sold through TD Cowen after our instruction will fluctuate based on a number of factors, including the
market price of our common stock during the sales period, the limits we set with TD Cowen in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate
during this offering, it is not currently possible